# Comparison of HDR vs. LDR Brachytherapy as Monotherapy for Intermediate Risk Prostate Cancer

> **NCT02692105** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **British Columbia Cancer Agency** · enrollment: 60 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **RADIATION:** Low dose rate prostate brachytherapy
- **RADIATION:** High Dose Rate prostate brachytherapy

## Key facts

- **NCT ID:** NCT02692105
- **Lead sponsor:** British Columbia Cancer Agency
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-05
- **Primary completion:** 2021-04
- **Final completion:** 2026-04
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02692105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02692105, "Comparison of HDR vs. LDR Brachytherapy as Monotherapy for Intermediate Risk Prostate Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02692105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*